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Bacterial DNAs are constantly detected in atherosclerotic plaques (APs), suggesting that a
combination of chronic infection and inflammation may have roles in AP formation. A
series of studies suggested that certain Gram-negative bacteria were able to interact with
dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin [DC-SIGN;
cluster of differentiation (CD) 209] or langerin (CD207), thereby resulting in deposition of
CD209s at infection sites. We wondered if Proteus mirabilis (a member of Proteobacteria
family) could interact with APs through CD209/CD207. In this study, we first
demonstrated that CD209/CD207 were also receptors for P. mirabilis that mediated
adherence and phagocytosis by macrophages. P. mirabilis interacted with fresh and
CD209s/CD207-expressing APs cut from human coronary arteries, rather than in healthy
and smooth arteries. These interactions were inhibited by addition of a ligand-mimic
oligosaccharide and the coverage of the ligand, as well as by anti-CD209 antibody. Finally,
the hearts from an atherosclerotic mouse model contained higher numbers of P. mirabilis
than that of control mice during infection-challenging. We therefore concluded that the P.
mirabilis interacts with APs in human coronary arteries via CD209s/CD207. It may be
possible to slow down the progress of atherosclerosis by blocking the interactions
between CD209s/CD207 and certain atherosclerosis-involved bacteria with ligand-
mimic oligosaccharides.
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Cardiovascular diseases caused by atherosclerosis are leading
causes of mortality worldwide (1–3). Plaque formation is a
hallmark of atherosclerosis (4) and is characterized by
deposition of fat, cholesterol and calcium in arterial intima.
Atherosclerosis in humans usually affects the “medium”
arteries, human coronary, renal, and carotid arteries (5). In
general, it is believed that risk factors such as hyperlipidemia,
hypertension, obesity, diabetes mellitus, and smoking can
contribute to the formation of atherosclerotic plaques (APs) (6–
9). However, the detailed molecular and biological mechanisms of
atherosclerosis are not clear.
Studies have suggested that risk factors may add to early
atherosclerotic lesions in human coronary arteries, which may
result in macrophage recruitment (7, 10). In fact, inflammation
and macrophage deposition have been observed in atherosclerosis
for decades (11–14). Macrophage-derived foam cells are major
players in atherosclerosis pathogenesis (15, 16). Initially, it was
thought that infiltrated macrophages could phagocytose lipid to
eliminate fat via scavenger receptors (17–19), but the infiltrated
macrophages in turn elicit an inflammatory response that damages
vessel walls (20). Several studies have shown that depletion of
macrophages in animals results in dramatic reduction of
atherosclerosis progression (21–24). Macrophages play a central
part in atherosclerosis development and AP destabilization. Hence,
scholars have explored therapeutic alternatives by depletion of
macrophages and inducing macrophage death (22, 24, 25).
Macrophage depletion also promotes AP stability and induces the
regression of established APs (24).
An increasing number of studies have shown that infections
(particularly chronic infections) are associated with the
development of cardiovascular diseases (7–9, 26–30). Bacteria
can infect vessel walls directly, thereby leading to their injury and
release of inflammatory factors (31). In some circumstances,
these bacteria can induce chronic infection residing within
antigen-presenting cells (APCs), such as dendritic cells (DCs)
or macrophages (30, 32–34). Also, monocytes in the circulation
may function as a “Trojan horse” to deliver bacteria from the
circulation to vessel walls and sustain the infection (7).
The presence of bacteria in APs has been demonstrated thanks
to advancements in DNA-sequencing methods (35–38). For
example, DNA from the Gram-negative bacteria Porphyromonas
gingivalis, Chlamydia pneumonia and Helicobacter pylori are often
detected in human APs (36). One study indicated that the
Proteobacteria phylum occupies 48.3% of bacterial profiles in
human APs (38). Canducci and colleagues indicated that
coronary APs can be stimulated to produce cross-reacting
antibodies against P. mirabilis (39). We think that Canducci and
coworkers might not recognize then that P. mirabilis had been
present in the APs that were used to produce anti-P. mirabilis
antibodies. Nevertheless, their study suggested that P. mirabilis in
APs was could stimulate inflammation. P. mirabilis is a member of
the Proteobacteria phylum. It is an opportunistic bacterium that can
cause urinary-tract infections, induce stone formation and, in some
rare cases, cause bacteremia (40, 41).Frontiers in Immunology | www.frontiersin.org 2Structurally, P. mirabilis is also a Gram-negative bacterium.
Over 70% of the surface of Gram-negative bacteria is occupied by
fully expressed lipopolysaccharide (LPS) that, in general, consists
of three structural regions (Figure 1): (i) lipid A, (ii) the
oligosaccharide (LPS) core and (iii) O-polysaccharide (OPS),
which is also known as or “O-antigen”. The LPS produced by
wild-type Gram-negative bacteria is recognized as “smooth LPS”,
whereas LPS lacking the O-antigen is known as “rough LPS” or
“lipo-oligosaccharide”. Acting like a shield, O-antigen can
promote resistance to serum killing and/or phagocytosis (42).
Lipid A is also known as an endotoxin, which are well-
documented inducers of inflammation.
A series of studies showed that many Gram-negative bacteria,
including Salmonella enterica serovar Typhimurium, Escherichia
coli, Yersinia pestis, Yersinia pseudotuberculosis, Neisseria
gonorrhoeae, Haemophilus ducreyi, and Shigella spp. can use
their LPS core to bind with immune receptors such as dendritic
cell-specific intercellular adhesion molecule-3-grabbing non-
integrin [DC-SIGN; also known as cluster of differentiation
(CD) 209] and human langerin (CD207) (43–51). DC-SIGN and
langerin belong to C-type lectins, which are usually expressed by
APCs, such as DCs, macrophages, and Langerhans cells (52, 53).
C-type lectins contain one or more carbohydrate-recognition
domain that can interact with carbohydrate ligands (54). For
example, the carbohydrates on glycoprotein 120 (gp120) of the
human immunodeficiency virus (HIV) can bind with DC-SIGN
to “hijack” APCs and promote host dissemination of the HIV to
T cells in lymph nodes (55, 56). Using similar mechanisms, it has
been suggested that Gram-negative S. typhimurium, Y. pestis and
Y. pseudotuberculosis exploit APCs to promote dissemination in
the host (47–51). A study by Ye and colleagues on S.
typhimurium, which causes typhoid fever in mice, speculated
that many interactions between CD209 and LPS core could lead
to CD209 deposition at infection sites (especially during chronic
infections) (51).
DC-SIGN has been detected on APs from the coronary
arteries of patients (13). The expressed DC-SIGN on APs was
co-localized with the classical macrophage markers CD14 and
CD68 (13). Carrione and colleagues found that DC-SIGN-
expressing DCs in myeloid cells could facilitate the traffic of P.
gingivalis (another Gram-negative bacterium) from the oral
mucosa to APs (57). Those studies indicated that DC-SIGN on
APCs might be involved in atherosclerosis development.
In the present study, we tested the hypothesis that P. mirabilis
may interact with APs from human coronary arteries through
DC-SIGN (CD209).MATERIALS AND METHODS
Ethics Statement
All animal procedures and human experiments were conducted
in strict accordance with the Institutional Animal Care and Use
Committees and Institutional Review Board (IRB) of Tongji
Hospital, Tongji Medical College, China. The handling of the
mice and all experimental procedures were specifically approvedJanuary 2021 | Volume 11 | Article 579010
Xue et al. Proteus mirabilis Interacts With Plaquefor this study by the Medical Ethics Committee of Tongji
Hospital and were carried out in accordance with institutional
guidelines (TJ-IRB20182677 for animal experiments and
TJ-IRB20182315 for human experiments). All procedures on
mice were performed under sodium pentobarbital anesthesia,
all efforts were made to minimize suffering, and all
volunteers involved in the experiment signed informed
consent. Twelve plaque samples were retrieved from coronary
arteries of patients with fatal coronary heart disease in Tongji
Hospital (Table 1).
Biological Reagents
Mannan, the ligand antagonist of the human mannose receptor,
was purchased from Sigma (St. Louis, MO, USA). Anti-human
DC-SIGN and anti-human Langerin monoclonal antibodies
(MAbs) were purchased from Pharmingen (San Diego, CA,
USA). Human Glu-plasminogen (Hematologic Technologies,
Essex Junction, VT, USA) and the chromogenic plasminFrontiers in Immunology | www.frontiersin.org 3substrate S-2251 (Chromogenix, Milano, Italy) were used in
the plasminogen activation assay.
Bacterial Strains (Table 2)
E. coli K-12 strain CS180 is E. coli with rough LPS missing the O-
antigen. CS1861 is the derivative of CS180 transformed with the
pSS37 plasmid, which contains all of the necessary genes for
O-antigen expression of the Shigella dysenteriae 1 (58). CS180-Pla
andCS1861-PlawereconstructedbyCS180andCS1861 transformed
with the pUC18-Pla plasmid expressing the plasminogen activator
(PLA) protein from Y. pestis, respectively (59).
Y. pestis 1418 originated from KIM5 (KIM D27), a strain,
whose pgm (pigmentation) gene has been deleted (60). Y.
pseudotuberculosis Y1 is a serotype O: 1a strain, lacking the
virulence plasmid (pYV), was used as a positive control in the cell
invasion assay (61).
A P. mirabilis strain was isolated from a urine sample from a
patient suffering from a chronic and recurrent urinary-tractTABLE 1 | The clinical information of patients.
Variable n = 12
Ages
(years)
53 49 41 58 67 44 60 55 60 59 60 58
Gender Male Male Female Female Male Male Male Female Female Male Female Male
Disease
diagnosis














































graftJanuary 2021 | Volume 11 | ArtiFIGURE 1 | Structure of the LPS core. Structures of the inner-core and outer-core regions of the LPS or LOS of E. coli K12, S. typhimurium, N. gonorrhoeae, and
P. mirabilis and the genes involved in their synthesis are presented. Genes encoding enzymes that are involved in the biosynthesis of core oligosaccharides are
shown along with lines that indicate the approximate sites at which the enzymes function (solid line). Sites that are variably substituted or still under investigation are
indicated by dashed lines. GlcNAc, N-acetyl-glucosamine; Glc, glucose; Hep, heptose; Gal, galactose; P, phosphate; PPEtn, phosphoethanolamine; KDO, 2-keto-3-
deoxyoctonate. E. coli K12 and N. gonorrhoeae naturally do not possess the O-antigen.cle 579010
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Clinical Laboratory Medicine of Tongji Hospital (Wuhan,
China). P. mirabilis-pAY100.1 is P. mirabilis that has been
transformed by plasmid pAY100.1. P. mirabilis-pAY100.1
carries all the genes necessary for expression of the O-antigen
of Yersinia enterocolitica serotype O:3 (62). P. mirabilis-Pla is the
strain expressing PLA. P. mirabilis O+-Pla is P. mirabilis that has
been transformed with pss37 and pUC-Pla plasmids (59).
Cell Lines
The CHO-hDC-SIGN and CHO-hLangerin cell lines were
generated by transfecting Chinese hamster ovary cells (CHO)
cells with corresponding human C-type lectin cDNAs. The
transfection was followed by G418 (1.5 mg/ml) selection and
screening for stable surface expression. CHO-NEO, which
expresses the neomycin resistance gene only, was the control
cell line (48–51). The RAW264.7 is a murine macrophage cell
line (Table 2). All the cells were cultured in DMEM
supplemented with 10% of fetal calf serum (FCS),
streptomycin (100 mg/ml), and penicillin (100 U/ml)
incubated overnight at 37°C with 5% CO2.
Mice
Male C57BL/6J mice, aged 6–8 weeks, were purchased from
Hunan SJA Laboratory Animal Co. Ltd (Hunan, China). The
mice were housed in animal facilities at the Tongji Hospital in
direct accordance with guidelines drafted by the Animal Care
Committee of Tongji Hospital.Frontiers in Immunology | www.frontiersin.org 4Isolation of Mouse Peritoneal
Macrophages
Peritoneal macrophages were chosen as our primary cells. After
female mice (6 to 8 weeks old) were euthanized, their intact
abdomen was exposed, cleaned with 70% ethanol and cut with
scissors. A 5 ml aliquot of RPMI was injected into the
intraperitoneal cavity. The mouse abdomen was gently
massaged for 2 min and then the lavage fluid was collected.
The collected macrophages were then used to perform invasion
assays. The peritoneal macrophages expressed high levels of
SIGNR1 as shown in previous study (46).
In Vitro Cell Invasion Assay with Cell Lines
The cell invasion assays were performed as described previously
(63). Host cells (CHO, CHO-hDC-SIGN, CHO-hLangerin,
RAW264.7, and peritoneal macrophages) were suspended in
RPMI supplemented with 2% FCS. One-half ml of cells was
plated in 24-well plates at the concentration of 105cells/well. The
RAW264.7 and peritoneal macrophages were seeded onto plates,
in which each well contained a 1.5-cm-diameter glass coverside,
to allow the cells to adhere quickly. The other host cells were
cultured overnight. 106 bacteria in total at the log phage of the
growth were used in the cell invasion assay. A 50 µl aliquot of
bacterial suspensions was added to the plate at a concentration of
1×107 colony-forming units (CFU)/ml. The cells were incubated
with the bacteria at 37°C for 2.5 h in the presence of 5% CO2.
The cells were washed three times with PBS. A 2 ml aliquot of 2%
FBS RPMI-1640 was added to each well with gentamycin whichTABLE 2 | Bacterial strains and cell lines used in this study.
Strain or cell line Characteristics References
Y.
pseudotuberculosis
Y1 O:1a, wild-type expressing invasion but with pYV plamid naturally cured (smooth) 61
Y. pestis
1418 Originated from KIM5 (KIM D27) with pgm (pigmentation) gene deleted 60
Y. enterocolitica Serotype O:3 This work
E.coli K-12
CS180 Wild-type (rough) 58
CS1861 CS180 expressing O-antigen (smooth) 58
CS180-Pla CS180 transformed with puc18-Pla plasmid expressing the PLA protein from Y. pestis This work
CS1861-Pla CS1861 transformed with puc18-Pla plasmid expressing the PLA protein from Y. pestis This work
P. mirabilis Isolated from clinical specimens This work
P. mirabilis-
pAY100.1
P. mirabilis transformed with pAY100.1 plasmid expressing an O-antigen from Y. enterocolitica serotype O:3 This work
P. mirabilis-Pla P. mirabilis transformed with puc18-Pla plasmid expressing the PLA protein from Y. pestis This work




CHO-NEO cells Control cell line, which expresses the neomycin resistance gene only
CHO-hDC-
SIGN cells
Generated by transfecting CHO cells with human DC-SIGN cDNAs
CHO-hLangerin
cells
Generated by transfecting CHO cells with human Langerin cDNAs
Primary
macrophage
Primary macrophages from mouse peritoneal cavity
RAW264.7 Murine macrophage cell lineJanuary 2021 | Volume 11 | Article 579010
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host cells at a final concentration of 100 mg/ml and incubated for
1 h. The cells were washed twice with PBS in the 24-well plate
twice. The cells were lysed with 1 ml 1% Triton X-100. The lysate
was diluted and put on a LB agar plate. The bacterial colonies
recovered from the lysed cells were counted the following day to
define the level of internalized bacteria in these host cells. All
experiments were performed in triplicate and data are expressed
as mean ± standard error.
In the inhibition experiment, the anti-hDC-SIGN/hLangerin
antibody was used at a concentration of 5 mg/ml and mannan
was used at a concentration of 500 mg/ml, 20 min before adding
the bacteria. The concentrations used in the experiments were
adapted from our previous studies. Neither the survival of
bacteria nor the cells were affected by the reagents added (45).
Cell Adherence Assay of Fresh Plaque
Tissue
Fresh plaque tissues were derived from human coronary arteries of
cardiovascular surgery patients recruited at Tongji Hospital for
cardiovascular surgery. The plaque tissues were carefully separated
from the coronary arteries using anatomical scissor and a scalpel
and cut into 2 mm3 pieces. The tissue pieces were suspended in
RPMI-1640 with 2% FCS and added to a 24-well plate containing
1ml/well. Triplicated wells were established for each experimental
group. The tissue samples were added to each well in a sufficient
quantity in order to minimize the intergroup variation. 106
bacteria in total at the log phage of the growth is used in the
adherence assay. A 50 ml aliquot of the bacterial suspension
(OD600 = 0.2) was added to each well and incubated at 37°C for
2 h. After 2 h, the plate was carefully washed with PBS. The plaque
tissues in the plate were collected and homogenized in 1% Triton
X-100 with a tissue grinder. The levels of adherence of bacteria on
the plaque sample were calculated by determining the CFU
recovered from the lysed tissue samples.
In the inhibition experiment, anti-hDC-SIGN antibody was
used at a concentration of 5 mg/ml, mannan at a concentration of
500 mg/ml and core LPS at the concentration of 200 mg/ml, 20 min
before the addition of bacteria. The concentrations used in the
experiments were adapted from our previous publications (45).
Plaque Bacteria DNA Profiling
Sequencing of the 16S ribosomal RNA (rRNA) genes is a
common method to detect the bacterial composition in
different samples (64, 65). 16S rRNA genes have highly
conserved sequences interspersed with nine viable regions.
Bacterial DNA in AP samples was extracted according to the
method described by Ott SJ and colleagues (66). Polymerase
chain reaction (PCR) amplification of 16S rRNA genes from the
nucleic acids of extracted bacteria was done using the
StepOnePlus™ Real-Time PCR System (Thermo Fisher
Scientific, Waltham, MA, USA). Precise bacterial profiles were
obtained by comparative analyses of the 16S rRNA gene of the
DNA extracted from AP samples. Analyses were achieved
through single-molecule real-time sequencing (SMRT)
technology (Pacific Biosciences, Menlo Park, CA, USA) (38).Frontiers in Immunology | www.frontiersin.org 5Long-read sequencing using SMRT technology can capture
the full-length the 16S rRNA sequence and determine the
microbial communities of the sample at genus and species
levels (67). SMRT can permit achievement of a relatively
unbiased view of the bacterial composition of AP samples.
Immunohistochemistry of Atherosclerotic
Plaques
Expression of human DC-SIGN/human langerin was examined
using anti-DC-SIGN/anti-langerin antibody-stained cells in all
APs. APs were fixed in 4% paraformaldehyde. Staining
(hematoxylin and eosin) was employed to demonstrate
infiltration of inflammatory cells and the histopathology of AP
samples (13). Immunohistochemical analyses for human DC-
SIGN/human langerin were undertaken for AP samples and AP
samples from asymptomatic patients with cardiovascular disease
using anti-human DC-SIGN/human langerin antibodies.
Briefly, AP tissues were cut into pieces of size 2–3 mm and
made into paraffin sections. Citrate buffer (pH 6.0) was used for
antigen retrieval for 7 min at 100 °C. Afterwards, the slides were
blocked with serum for 1 h and incubated with primary antibodies
against human DC-SIGN (Pharmingen, San Diego, CA, USA) for
1 h. After washing slides thrice with PBS, they were incubated with
the corresponding secondary antibody for 1 h. The slides were
examined under an ECLIPSE CI microscope (ECLIPSE CI, Nikon,
Japan) and analyzed with ImageJ 1.50 (National Institutes of
Health, Bethesda, Maryland, USA) software.
Extraction of Proteus mirabilis
Lipopolysaccharide
P. mirabilis and P. mirabilis-pAY100.1 were analyzed for the O-
antigen profile by silver staining. Y. enterocolitica cultured at 26°
C and 37°C was used as a control in this experiment. Bacterial
LPS were extracted with a LPS extraction kit (iNtRON
Biotechnology, Daejeon, Korea) according to the protocol sheet
from the manufacturer’s instructions. Briefly, the bacterial
strains were grown in LB medium at 37°C for 24 h. The
bacteria underwent synchronization to an optical density of
1.0 at 600 nm. The bacterial pellets were harvested at room
temperature after centrifugation at 13,000 rpm for 30 s. The
pellets were washed by three times in phosphate-buffered
saline (PBS), suspended in 1 ml bacterial Lysis Buffer and
vortexed vigorously to liberate the nucleic acids, proteins, and
cell wall components. A 200 ml aliquot of chloroform was
added to the suspension. The mixture was mixed vigorously by
votexing for 10–20 s and incubated at room temperature for
5 min. The samples were centrifuged at 13,000 rpm for 10 min
at 4°C. The LPS in the aqueous phase was collected. An 800 µl
aliquot of Purification Buffer was added to the supernatant,
mixed and incubated for 10 min at −20°C. The mixture
was centrifuged three times for the third times to pellet
the extracted LPS (15 min at 13,000 rpm at 4°C). A 1 ml
aliquot of 70% EtOH was added to wash the extracted LPS, and
the pellet was dried completely. A 70 ml aliquot of Tris-HCL
(10 mM pH8.0) was added to the extracted LPS to dissolve
the LPS.January 2021 | Volume 11 | Article 579010
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Gel Electrophoresis of Lipopolysaccharide
Samples From Proteus mirabilis Using
Silver Staining
To undertake further analyses of O-antigen expression of P.
mirabilis, LPS extracted from P. mirabilis and P. mirabilis-
pAY100.1 was analyzed for O-antigen expression by a silver
staining kit (Solarbio Science & Technology, Beijing, China)
according to a method we have described previously (68).
Purified LPS was resuspended in 5× loading buffer. Samples
(10 µl) were subjected to SDS-PAGE. After SDS-PAGE, the gel
was transferred to a clean glass dish and fixed with Fixation
Solution for 30 min. Next, the gel was transferred to Sensitizing
Solution, allowed to incubate for 30 min at room temperature
and agitated gently. The gel was washed twice with deionized
(10 min each time). After washing, the gel was transferred to
Silver Staining Solution, and agitated for 40 min at room
temperature. Next, the gel was transferred to Color-substrate
Solution and allowed to incubate for 10 min; the reaction was
terminated at a set time and Stop Solution was added. Finally, the
signals on the gel were acquired by a gel imager (Bio-Rad
Laboratories, Hercules, CA, USA).
Plasminogen Activation Assay
Plasminogen activation was measured, according to a method
published previously (51, 59). Briefly, P. mirabilis suspended in
PBSwasmixedwith 4mg of humanGlu-plasminogen and 0.45mM
S-2251 in 96-well plates in a total volume of 200 ml at 37°C. The
absorption values at 405 nm were measured at 30 min intervals. Y.
pestis 1418, which possesses high plasminogen activity, was used as
the positive control. The results are presented as the difference
between each measurement value and the starting value. The P.
mirabilisused in this studywas froma clinical isolate, and our silver
staining experiment showed that the LPS lacked the expression of
theO-antigen, which indicated that the core LOS of the P.mirabilis
was exposed. The expression of O-antigen on the rough strain of P.
mirabilis was reported by other researchers (69). The O-antigen
expression might be modified by the in vivo environment or
antibiotic therapeutic. The rough of Gram negative bacteria
shows proteolytic enzyme activity that degrades plasminogen to
plasmin (59, 70). The proteolytic enzyme requires rough LPS to
function but is specifically inhibited by the O-antigen present in
smooth LPS (59, 71). The proteolytic enzyme activity of the bacteria
is used as an index to assess the degree of exposure of the LPS core in
certain Gram negative bacteria (59, 71). We examined plasmin
activity of P. mirabilis and further confirmed that P. mirabilis used
in the current study was a strain that may expose the core LPS.
Purification of the Core Oligosaccharide of
Proteus mirabilis
The core oligosaccharide (LPS) of P. mirabilis was purified
according to a method described previously (45, 72). Purified
LPS was hydrolyzed in 0.1 M sodium acetate (pH 4.5) for 4 h at
100°C. A Dowex® 50WX8 column (Sciencelab, Dickinson, TX,
USA) was used in centrifugation to remove the sodium. Lipid A
was removed by an ultrafiltration device based on a molecularFrontiers in Immunology | www.frontiersin.org 6mass of 100 kDa. The remaining core oligosaccharide
was lyophilized.
Curves of Bacterial Growth
P. mirabilis and P. mirabilis-pAY100.1 were cultured in lysogeny
broth (LB) medium with shaking at 37°C until the logarithmic
phase was reached. The bacterial suspensions were diluted (1:100)
into 5 ml of LB medium and grown at 37°C with shaking at 200
rpm. Bacterial absorption at 600 nm was monitored at 1 h intervals
using a spectrophotometer (Thermo-Scientific, Waltham, MA,
USA). The growth curve was analyzed with Prism 6 (GraphPad,
San Diego, CA, USA).
Flow Cytometry
We wished to supplement the phagocytosis assay, so flow
cytometry was employed. P. mirabilis in suspensions were
stained by adding carboxyfluorescein diacetate-succinimidyl
ester (CFDA-SE) fluorescent probes (Beyotime Biotechnology,
Beijing, China) as described previously (48). The bacterial
suspension (2 × 105 CFU) was stained with CFDA-SE
fluorescent probes (10 mM) for 40 min at room temperature in
the dark. The bacterial suspension was washed twice in
phosphate-buffered saline (PBS). Cells (1 × 105) in each well
were inoculated with bacteria for 2 h in a 24-well plate. Peritoneal
macrophages from mice incubated with unlabeled bacteria were
served as negative controls. Cells were washed twice with RPMI
buffer to remove excess dye. After incubation, the extracellular
fluorescent signals were quenched by 0.4% Trypan blue for
10 min. (Trypan blue can quench extracellular fluorescence
signals but cannot enter living cells.) Cells were washed twice
with PBS and digested by 0.25% Trypsin. Samples were analyzed
by flow cytometry at fluorescent intensity of the FL-1 channel.
Bacterial Infection in an Atherosclerosis
Model With Apolipoprotein E Knockout
Mice
P. mirabilis was cultured at 37°C until reaching absorbance (at
600 nm) of 1. Bacterial suspensions were diluted with PBS at a
final concentration of 4×107. After intraperitoneal injection of
chloral hydrate, ApoE−/− mice and C57BL/6J mice (eight mice in
each group) were infected with P. mirabilis (100 µl, i.v.). C57BL/
6J mice were fed a normal diet for the same period as that used
for non-atherosclerotic controls. At 2, 12, 24, and 48 h after
injection, mice were anesthetized (chloral hydrate, i.p.). The
pleural cavity was opened. Cardiac perfusion was undertaken
using 50 ml of physiologic (0.9%) saline through the left ventricle
of the mice after making a small incision in the right auricle.
After cardiac perfusion, mice hearts were collected and
homogenized in 1% Triton X-100 using a tissue grinder.
Cardiac levels of bacteria were calculated by determining the
CFUs recovered from lysed tissue samples.
Adherence of Proteus mirabilis to the
Heart Tissues of Mice
P. mirabilis and P. mirabilis-pAY100.1 were used to ascertain the
adherence of P. mirabilis to the heart tissue of ApoE−/− mice andJanuary 2021 | Volume 11 | Article 579010
Xue et al. Proteus mirabilis Interacts With Plaquewild-type mice. The hearts of ApoE−/− mice were cut into pieces
at a final area of 1 mm3. These tissue pieces were plated in a 24-
well plate. Bacteria (2×106) at the log phase of growth were used
in the adherence assay. P. mirabilis and P. mirabilis-pAY100.1
(absorbance at 600 nm = 0.2) were added to each well at a
volume of 100 µl and incubated for 2 h at 37°C. Then, the tissue
pieces were washed thrice with PBS. Heart tissues were collected
and homogenized in 1% Triton X-100 by a tissue grinder. The
levels of adherence of bacteria on heart tissues were quantified by
determining the CFU recovered from lysed tissue samples.
Statistical Analyses
All statistical analyses were completed using Prism software,
version 6 (Graph Pad, SanDiego, CA, USA). Statistical
significance was assessed using Student’s unpaired t-test for the
univariate analysis of two sets of data.RESULTS
Proteus mirabilis Used in the Study May
Not Have Expressed O-Antigen
P. mirabilis may be associated with AP formation (38, 39). Thus,
P. mirabilis was chosen to investigate the possible roles of
bacterial infection in atherosclerosis. P. mirabilis is a Gram-
negative bacterium. It can are classified as “smooth” or “rough”
based on the presence or absence of O-antigen, respectively (46,
73, 74). It was necessary to determine whether this P. mirabilis (a
clinical isolate from Wuhan) was a smooth or rough strain. In
addition, according to our previous works, O-antigen expression
reduces the ability of several species of Gram-negative bacteria to
target DC-SIGN, langerin, and DEC-205 (CD205) in humans
(43–51). Hence, we also constructed the P. mirabilis-pAY100.1Frontiers in Immunology | www.frontiersin.org 7strain, which shows full expression of the O-antigen from Y.
enterocolitica. SDS-PAGE with silver staining was undertaken on
P. mirabilis and its isogenic derivative P. mirabilis-pAY100.1.
Compared with P. mirabilis-pAY100.1, P. mirabilis did not
express the full O-antigen chain (Figure 2B). O-antigen
expression by Y. enterocolitica and Y. pseudotuberculosis at
37°C was inhibited (75, 76) (Figure 2A).
Proteus mirabilis Used in our Study was
the Rough Strain
A method which measures the activity of PLA enzyme from Y.
pestis was applied to verify that the P. mirabilis used in the
present study was a rough strain (59, 70). This method was
developed originally by Kukkonen et al. They found that PLA
activity can be achieved only in O-antigen-deleting bacteria
(59). That is, the higher the PLA activity, the shorter is the
O-antigen in Gram-negative bacteria. The same method
was also utilized in our recent study on S. typhimurium (51).
The rationale for using this method is detailed in the
Discussion section.
Therefore, we constructed strains of P. mirabilis-Pla and P.
mirabilis O+-Pla. Y. pestis 1418 is the original strain that codes
PLA, and was used as the positive control (51). Meanwhile, we
used Escherichia coli CS180-Pla and E. coli CS1861-Pla as
controls (51). E. coli CS180 belongs to the E. coli K-12 strain,
which usually does not express O-antigen. CS1861 is a CS180
strain that shows full expression of O-antigen. We have used this
pair of strains in many of our previous studies (43–51). P.
mirabilis-Pla expressed active PLA but, in contrast, PLA
activity on P. mirabilis O+-Pla was inhibited (Figure 2B). This
result further indicated that the P. mirabilis used in our study was
O-antigen-deleted or that the length of O-antigen was reduced,
which could allow exposure of the LPS core.A B
FIGURE 2 | The P. mirabilis used in this study is a rough strain. (A) Bacterial LPS structures were determined by a silver-stained SDS-PAGE. Lane 1: Y.
enterocolitica 26°C; lane 2: Y. enterocolitica 37°C; lane 3: P. mirabilis; lane 4: P. mirabilis-pAY100.1. The lipid A and core oligosaccharide, as well as the O-antigen
chain are indicated. (B) Plasminogen enzyme activity was used to evaluate the level of LPS core exposure of the P. mirabilis. The samples presented are: Yersinia
pestis 1418, P. mirabilis-Pla, P. mirabilis O+-Pla, 180-Pla, 1861-Pla, and PBS. The data were pooled from three independent experiments.January 2021 | Volume 11 | Article 579010
Xue et al. Proteus mirabilis Interacts With PlaqueProteus mirabilis Invades CD209-
Expressing Macrophages Effectively
APCs such as macrophages and DCs from the mouse
peritoneum express CD209 receptors on their surface, which
can interact with the LPS core for invasion (43–46, 49–51). Given
the possible exposure of the LPS core for P. mirabilis (Figures
2A, B), we tested the ability of P. mirabilis to invade CD209-
expressing macrophages (49–51) and a macrophage cell line that
lacks expression of CD209 receptors (77) (RAW264.7) (data not
shown). The E. coli K-12 strain of CS180 (with rough LPS) and
CS1861 (a CS180 strain fully expressing O-antigen) bacteria were
used as controls (43). Gentamicin protection and flow cytometry
were used to determine the rate of invasion. P. mirabilis invaded
primary macrophages much more effectively than it invaded
RAW264.7 cells (Figure 3A). Furthermore, we used CFDA-SE to
label P. mirabilis. As determined by flow cytometry. 44.2% of
macrophages were labeled with high efficiency, whereas 10.8% of
the bacteria exhibited weak fluorescence in RAW264.7 cellsFrontiers in Immunology | www.frontiersin.org 8(Figure 3B). The growth rate of P. mirabilis was not
influenced by expression of exogenous O-antigen (data not
shown), as has been shown with other Gram-negative bacteria
(48–51).
These results indicated that CD209s might have a role in
interacting with P. mirabilis.
Dendritic Cell-Specific Intercellular
Adhesion Molecule-3-Grabbing Non-
Integrin and Langerin Are Receptors for
Proteus mirabilis
CD209-expressing macrophages (13, 46, 49–51) phagocytosed
more P. mirabilis than macrophages that did not express CD209
(Figure 3A). Then, we used a stably transfected CHO cell line
that expresses hDC-SIGN (CHO-hDC-SIGN) and hLangerin
(CHO-hLangerin) to test their ability to phagocytose P.
mirabilis. We have used these cell lines in many of our
previous studies (43–51).A
B
FIGURE 3 | P. mirabilis interacts with CD209-expressing macrophages. Gentamicin protection- and flow cytometry-based assays were used to determine the
invasion abilities of Y. pseudotuberculosis Y1, E. coli K-12 (CS180, CS1861), and P. mirabilis into primary macrophages that express CD209 and the RAW 264.7
macrophage cell line, which does not express the CD209. Data from the gentamicin protection assay and flow cytometry are shown in (A, B), respectively.
Macrophages incubated with labeled and unlabeled bacteria are indicated by gray and black curves (B). The data were pooled from three independent experiments.
*P < 0.05, **P < 0.01.January 2021 | Volume 11 | Article 579010
Xue et al. Proteus mirabilis Interacts With PlaqueFirst, the gentamicin-protection assay was used to ascertain
the rate of invasion. The Y. pseudotuberculosis strain Y1 grown at
26°C has been shown to interact with cells between invasion and
its receptor, b-integrin, which is unaffected by other cell-surface
molecules (78). Y1 has been used as positive controls. E. coli
CS180 and CS1861 were used as controls (47, 48, 50, 51).
P. mirabilis invaded CHO-hDC-SIGN and CHO-hLangerin
cells more effectively than CHO-Neo cells (Figures 4A, B). In
addition, P. mirabilis-pAY100.1 could not promote the invasion
of cells expressing CHO-hDC-SIGN or CHO-hLangerin,
indicating that O-antigen expression blocked interactions
between P. mirabilis and CD209/CD207. Therefore, we
concluded that hDC-SIGN and hLangerin function as
receptors and contribute to the phagocytosis of P. mirabilis.
To confirm the specificity of this interaction, we examined
whether the host–pathogen interaction could be inhibited by anti-
hLangerin antibody, anti-hDC-SIGN antibody, and mannan
(antagonist of mannose receptors) (43–46, 48, 50, 51). E. coli
CS180, which mediates hDC-SIGN/hLangerin-dependent
interactions, was used as the control. The invasion of hDC-SIGN
and hLangerin by P. mirabilis was blocked by addition of both
inhibitors (Figures 4C, D).
The results shown above demonstrated that a specific
interaction between hDC-SIGN/hLangerin-P. mirabilis
promoted the invasion of this bacterium.Frontiers in Immunology | www.frontiersin.org 9Dendritic Cell-Specific Intercellular
Adhesion Molecule-3-Grabbing Non-
Integrin Was Expressed in All
Atherosclerotic Plaques of Coronary
Arteries Tested, but Not in Healthy Arteries
We measured expression of DC-SIGN and langerin in all
samples. DC-SIGN expression was detected in the inflamed
areas of arteries from all AP samples (Figure 5A) but not from
the normal arteries (Figure 5B). Furthermore, all samples were
stained for human langerin. Only one plaque showed langerin
expression (Figure 5C). Healthy arteries did not express langerin
(Figure 5D).
In summary, all APs expressed DC-SIGN, and one of them
expressed DC-SIGN and langerin.
Proteus mirabilis Interacted With APs,
Which Was Inhibited by Anti-hDC-SIGN,
Mannan Oligosaccharides, Core
Lipopolysaccharide of Proteus mirabilis as
Well as Coverage of the
Lipopolysaccharide Core With O-Antigen
It was clear that P. mirabilis interacted with hDC-SIGN.
However, whether P. mirabilis would interact with hDC-SIGN
detected on APs was not known. Therefore, we tested the abilityA B
DC
FIGURE 4 | hDC-SIGN and hLangerin are receptors for the rough P. mirabilis. (a) P. mirabilis invades the CHO cell line that expresses hDC-SIGN and hLangerin. Y.
pseudotuberculosis (Y1); E coli K-12 (CS180 and CS1861); P. mirabilis and P. mirabilis-pAY100.1 were examined for their ability to invade CHO/CHO-hDC-SIGN (A)
and CHO/CHO-hLangerin cells (B) using the gentamicin protection assay. The number of phagocytosed bacteria was determined by counting the recovered CFUs.
The data were pooled from three independent experiments. ***P < 0.001, ****P < 0.0001. b The interactions between P. mirabilis with CHO-hDC-SIGN and CHO-
hLangerin were blocked by the anti-hDC-SIGN antibody, by mannan oligosaccharides by shielding the ligand of the LPS core by expressing the O-antigen. (C) P.
mirabilis was incubated with CHO-hDC-SIGN for 2 h in the presence or absence of anti-hDC-SIGN and mannan. The phagocytosis rate of P. mirabilis was evaluated
by recovering the bacteria from the gentamicin protection assay. E. coli K12 CS180 was used as the control strain to show the core LPS-dependent interaction with
hDC-SIGN. (D) Anti-hLangerin and mannan were examined for their ability to inhibit the interaction between CHO-hLangerin and P. mirabilis. The data presented
were pooled from three independent experiments. ***P < 0.001, ****P < 0.0001.January 2021 | Volume 11 | Article 579010
Xue et al. Proteus mirabilis Interacts With Plaqueof P. mirabilis to adhere to APs (which were cut into pieces of ~1
mm3). The E. coli strains of CS180 and CS1861 were used as
controls. P. mirabilis-pAY100.1 and CS1861 were regarded as
“ligand-shielded” strains.
P. mirabilis and CS180 adhered to APs more effectively than
that observed in healthy arteries and smooth arteries (Figure 6A).
More importantly, P. mirabilis-pAY100.1 barely adhered to APs.Frontiers in Immunology | www.frontiersin.org 10We wished to verify that the interactions of P. mirabilis with
APs were via hDC-SIGN. Hence, we examined if the adherence
of P. mirabilis to APs could be inhibited by anti-hDC-SIGN and
mannan. The adherence of plaques by P. mirabilis was reduced
by addition of anti-hDC-SIGN and mannan, respectively (Figure
6B). Nevertheless, this reduction was not complete, suggesting
that additional receptors for P. mirabilis were present on APs.FIGURE 5 | All coronary arteries with plaques, but not healthy human arteries expressed DC-SIGN. Immunostaining for DC-SIGN and Langerin using the brown
immunoperoxidase (DAB) technique was described in the materials and methods section. (A) DC-SIGN expression was detected in all human coronary plaques.
(B) DC-SIGN expression was not detected in normal human arteries. (C) Langerin was expressed in one human coronary plaque. (D) Langerin was not expressed in
normal human arteries. Magnification: ×200 in (A–D.)A B
FIGURE 6 | P. mirabilis interacts with atherosclerotic plaques, which was inhibited by the anti-hDC-SIGN antibody, mannan oligosaccharide, as well as by covering
the ligand. A similar approach to Figure 4, the arteries with atherosclerotic plaques were regarded as CHO-DC-SIGN, respectively. (A) The two sets of bacteria
including E. coli K-12 strains (CS180 and CS1861), P. mirabilis, and P. mirabilis-pAY100.1 were incubated with atherosclerotic plaques to determine the adherence
ability of the plaques. (B) P. mirabilis was incubated with atherosclerotic plaques for 2 h in the presence or absence of anti-hDC-SIGN, mannan, and core
oligosaccharide from P. mirabilis. E. coli K12 CS180 was used as the control strains. The data were pooled from three independent experiments. ***P < 0.001,
****P < 0.0001.January 2021 | Volume 11 | Article 579010
Xue et al. Proteus mirabilis Interacts With PlaqueWe wished to ascertain if the interaction between P. mirabilis
and APs was mediated by binding of the core LPS of P. mirabilis
and CD209. Hence, we further examined the inhibition efficiency
of the core LPS from P. mirabilis in the interaction with APs. We
found that the core LPS purified from P. mirabilis could inhibit
the binding between bacteria and APs markedly. This result
suggested that the O-antigen of P. mirabilis was truncated and
that the core LPS of P. mirabilis was exposed. Hence, we
concluded that the interaction between the core LPS of P.
mirabilis and CD209 cell receptors of the host had major roles
in mediating adherence between bacteria and APs.
In summary, these results showed that P. mirabilis interacted
with APs. This interaction was inhibited by anti-hDC-SIGN,
mannan oligosaccharides, core LPS as well as coverage of the LPS
core with O-antigen.
The Proteobacteria Phylum Was One of
the Most Dominant Microbiota From One
Atherosclerotic Plaque Used in our Study
We employed standard technology for 16S rRNA sequencing to
investigate the microbiota from two AP samples. Across the two
samples, 7,000 sequences selected per sample were used for
statistical analyses. Operational taxonomic units (OTUs) were
applied to illustrate the abundance of each bacterial family at the
phylum level in APs. The highest proportion of OTUs identified
in AP sample 1 was for bacteria belonging to the phyla
Proteobacteria (68.6%), followed by Firmicutes and
Bacteroidetes (Figure 7). The highest proportion of OTUs in
AP sample 2 was for bacteria of phyla Firmicutes(30.1%),
followed by Proteobacteria, Bacteroidetes, Actinobacteria, and
unclassified phyla.
Collectively, the bacterial profiles from AP sample 1 were
similar to data from a study by Bergstrom and coworkers (38).
However, the bacterial abundance in AP sample 2 was very
different from that in AP sample 1, which revealed the intricacyFrontiers in Immunology | www.frontiersin.org 11of the association of bacteria and atherosclerosis development. P.
gingivalis (the most discussed Gram-negative bacterium due to
its involvement in Alzheimer’s disease) belongs to the phylum
Bacteroidetes (79–81).
Proteus mirabilis can Reach the Heart of
ApoE−/− Mice
We demonstrated that P. mirabilis could interact with human
coronary APs through DC-SIGN. We wished to further
investigate the role of P. mirabilis in animals suffering from
atherosclerosis. Hence, we infected ApoE−/− mice fed a high-
fiber diet with P. mirabilis through the intravenous route; wild-
type mice were used as controls. At 2, 12, 24, and 48 h after
infection, substantial levels of bacteria were present in the hearts
of ApoE−/− mice after grinding mice-heart tissue, and reached a
peak at 24 h (Figure 8). In contrast, wild-type mice had fewer
bacteria in their heart tissue. Significantly, we analyzed the
survival curve of mice and found that P. mirabilis was more
lethal to the atherosclerotic mice than the wide type mice (data
not shown). These results indicated that, as important
inflammatory sites, APs can recruit P. mirabilis in the blood
stream and cause persistent infection.
Proteus mirabilis Interacts With Heart
Tissues From ApoE−/− Mice
We examined the adherence of P. mirabilis with heart tissues
from ApoE−/− mice and wild-type mice. P. mirabilis and P.
mirabilis-pAY100.1 were incubated with heart tissues from
ApoE−/− mice and wild-type mice. The E. coli K-12 strains of
CS180 and CS1861 were used as controls (43). Adherence of P.
mirabilis with the heart tissues of ApoE−/− mice was higher than
that in wild-type mice, and P. mirabilis-pAY100.1 had lower
adherence to the heart tissue of ApoE−/− mice compared with
that of P. mirabilis (Figure 9). This result was consistent with the
results from the adherence assay of P. mirabilis with APs.FIGURE 7 | Members of the microbiota that differ in abundance between the plaque samples. The bacterial abundances OTUs of each plaque sample were plotted
based on the abundances after sequencing 7,000 selected sequences in each phylum. The proportion rate of OTUs was identified by the length of the column.January 2021 | Volume 11 | Article 579010
Xue et al. Proteus mirabilis Interacts With PlaqueDISCUSSION
At the USA in the early-1900s, there was a notorious case of
latent bacterial infection, “Typhoid Mary”, which led to many
cases of infections and deaths. As a chef, Mary Mallon was able to
transmit a bacterial species, Gram-negative Salmonella typhi to
many people. This transmission lasted for decades because she
was an asymptomatic carrier, who carried a bacterium that could
lead to chronic infections in humans (30). Using S. typhimurium
(the cause of typhoid in mice), we speculated that an interaction
between the LPS core and CD209s may contribute to chronic
infections by Salmonella in the host (51). This speculation was
based on a series of studies between the LPS core and C-type
lectins that we carried out (43–51).Frontiers in Immunology | www.frontiersin.org 12Besides the lessons learned from Typhoid Mary, studies have
unveiled a molecular mechanism of chronic bacterial infections,
including Gram-negative bacteria-associated Crohn’s disease,
Helicobacter pylori-associated chronic atrophic gastritis
(ChAG), P. gingivalis-associated Alzheimer’s disease and
Mycobacterium tuberculosis-associated tuberculosis (78, 81–92).
These bacteria all share a common characteristic: they can
interact with CD209s and survive (and even replicate) within
macrophages (34, 78, 84–87). Furthermore, Dr. Helaine and
collaborators discovered that phagocytosed S. typhimurium can
form persistently within macrophages (30). Thus, macrophages,
which are supposed to be the “warriors” of innate immunity, are
in turn utilized as a “shelter” for a persistent bacterial infection
(30, 34).FIGURE 9 | P. mirabilis showed higher adherence with the heart tissues of ApoE−/− mice compared with that by P. mirabilis-pAY100.1. Two sets of bacteria
(Escherichia coli K-12 strains CS180/CS1861 and P. mirabilis/P. mirabilis-pAY100.1) were incubated with the heart tissues of ApoE−/− mice to determine bacterial
adherence. *P < 0.05, **P < 0.01.FIGURE 8 | Presence of P. mirabilis in mice heart tissues. Mice were infected with P. mirabilis (4×107 CFU) through the intravenous route. After 2, 12, 24, and 48 h,
the homogenized heart samples were cultured in LB medium, and bacteria were recovered. (A) CFU counts in the hearts of ApoE−/− mice and wild-type mice. ***P <
0.001, ****P < 0.0001.January 2021 | Volume 11 | Article 579010
Xue et al. Proteus mirabilis Interacts With PlaqueIncreasing evidence suggests that macrophages, inflammation
and chronic infection are involved in atherosclerosis pathogenesis
(14, 88). We hypothesized that if atherosclerosis is due to chronic
infection, it may have similar characteristics to that of chronic
infection caused by Salmonella species.
We wondered where AP-colonized bacteria were coming
from. In general, it is believed that the microbial communities
in APs are like those colonizing other parts of the human body;
they are highly diverse and have variable features between
individuals (89). Koren et al. reported that bacteria from the
oral cavity and gastrointestinal tract could be the main sources of
bacteria in APs (90). In the present study, we speculated that the
consequences of the interaction between P. mirabilis and CD209/
CD207 might follow a similar molecular mechanism to how the
HIV and several Gram-negative bacteria disseminate (47–51,
55). That is, P. mirabilis may also hijack APCs by interacting
with CD209s for its dissemination to coronary arteries and to
promote atherosclerosis development.
We wished to further investigate the role of bacterial infection in
atherosclerosis in vivo and to elucidate how the interaction between
C-type lectins and pathogens can promote the pathogenesis of
human atherosclerosis in vivo. Hence, we infected P. mirabilis
through the intravenous route in ApoE−/− mice fed a high-fat diet
(91–93). Our data showed that P. mirabilis could colonize the heart
of mice as early as 2 h after injection. Also, the mice showed
dyslipidemia, which suggested that atherosclerosis had occurred.
We also utilized the heart tissues of ApoE−/− mice and wild-type
mice in the bacteria adherence assay. P. mirabilis showed higher
adherence to the heart tissues of ApoE−/−mice compared with that of
P. mirabilis-pAY100.1 (Figure 9). This result further supported the
notion that macrophages in APs can bind with P. mirabilis, and that
O-antigen expression inhibited the binding of bacteria with AP tissues.
In future research, it will be important to ascertain if this
mechanism is present in other chronic infectious diseases. For
example, colonization of bacteria such as P. gingivalis has been
noted in Alzheimer’s disease. P. gingivalis is involved mainly in
gingival and periodontal infections (80, 81). Those studies
offered us inspiration that bacterial infection is involved in the
development of diseases such as cancer, cardiovascular diseases,
and Alzheimer’s disease. Specifically, how these bacteria reached
the target organ from peripheral organs attracted our interest.
Previously, we demonstrated consistently that external
expression of O-antigen can block exposure of the core LPS
(47–51). For example, we showed that a series of Gram-negative
bacteria (S. typhimurium, E. coli, N. gonorrhoeae) invaded APCs
through binding of the core LPS with DC-SIGN (45). This
interaction could be inhibited by external expression of O-
antigen (45). We could not exclude the possibility that other
factors are involved in this interaction, but the interaction
between DC-SIGN and the LPS core plays a major part in the
phagocytosis of pathogens. When the ligand or receptor mimics
were added, or there was overexpression of the O-antigen, the
ability of APCs, macrophages and DCs to phagocytose pathogens
was reduced. We have also shown that certain oligosaccharides
and polysaccharides can inhibit the interaction between the LPS
core and CD209/207 (43–51). In fact, oligosaccharides, glycanFrontiers in Immunology | www.frontiersin.org 13and the DC-SIGN-like protein Mermaid can inhibit the binding
of DC-SIGN with gp120 of the HIV (45–48, 50, 94–97). LewisX
components (oligosaccharides) from human milk can block the
interaction between DC-SIGN and gp120 (98). The structure of
LewisX components is similar to that of core LPS, and purified
LPS core can inhibit the interaction between CD209/207 and the
LPS core (45, 48, 49). Thus, certain oligosaccharides could be
developed as therapeutic candidates for atherosclerosis (48, 99).CONCLUSIONS
We demonstrated that human DC-SIGN (CD209) expressed on
APs could serve as a cellular receptor for P. mirabilis (a Gram-
negative bacterium that can induce an inflammatory response
while colonizing APs) (100). This host–pathogen interaction
could be inhibited by blockade of the binding sites for
receptors (CD209 or CD207) or carbohydrate ligands (Figure 6).
Finally, we would like to borrow a comment fromGarcia-Vallejo
and van Kooyk: “These manuscripts, call, once again, our attention
on the largely unexplored field of bacterial glycosylation, one of the
new frontiers of modern glycobiology” (101). The manuscripts they
were referring to were four of our publications (45–48). We believe
that “these manuscripts” should have included our three recent
publications (49–51). These seven publications indicate one fact:
blockade of the interactions between the C-type lectins (CD205,
CD207, CD209) and carbohydrates of bacteria inhibit bacterial
interactions with the host, dissemination, and infection. Blockade of
the interaction between human DC-SIGN with bacterial
carbohydrates or receptor mimics (e.g., Mermaid) in APs could
initiate a new frontier of therapies for atherosclerosis.DATA AVAILABILITY STATEMENT
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